Walleye Capital
STOK icon

Walleye Capital’s Stoke Therapeutics STOK Stock Holding History

Walleye Capital’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-126,830
Closed -$1.71M – 5836
2024
Q2 		$1.71M Buy
+126,830
New +$1.71M ﹤0.01% 2254
2023
Q4 		– Sell
-67,351
Closed -$265K – 5487
2023
Q3 		$265K Buy
+67,351
New +$443K ﹤0.01% 3337
2021
Q2 		– Sell
-24,100
Closed -$936 – 1502
2021
Q1 		$936 Buy
+24,100
New +$1.37M 0.05% 323

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Walleye Capital's STOK Position: Q3 2024 in Review

Walleye Capital sold out of Stoke Therapeutics (STOK) in Q3 2024, closing a stake of 126,830 shares — an estimated $1.71M sold.

Walleye Capital first reported a position in STOK in Q1 2021 and held it in 3 quarters. The position peaked at $1.71M in Q2 2024. 118 funds tracked by Wall St. Rank hold STOK as of Q3 2024.

  • Walleye Capital reported no remaining Stoke Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Walleye Capital sold 126,830 Stoke Therapeutics shares in Q3 2024, an estimated $1.71M.
  • Walleye Capital first reported a position in Stoke Therapeutics in Q1 2021 and held it in 3 quarters.
  • Walleye Capital's Stoke Therapeutics position peaked at $1.71M in Q2 2024.
  • 118 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2024.

Based on Walleye Capital's 13F filing for Q3 2024, filed 14 Nov 2024.